Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
CVS Health Corp.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
Weak signals across every dimension
1 of 5 met · composite in line with peers
Business quality, valuation against the sector, and position in the 52-week range — whether they line up or not.
Stable quality
Profitability
3/4
Debt & liquidity
1/3
Efficiency
2/2
Valuation is the clearest positive here: P/B sits -71% below the sector median at 1.7×, and FCF yield of 5.7% runs +41% above the median — the stock is cheap on cash-return terms. The F-Score of 6/9 reflects a mixed picture, with profitability holding up but the balance sheet under pressure; Debt/EBITDA of 6.5× exceeds the sector median by +123%, and operating margin of 1.2% trails the sector median by -94%. The composite of 37/100 against the sector median captures that tension — cheap multiples sitting alongside weak quality and strained finances. On the forward axis, consensus lines up with the realized track record, and the beat rate is strong, though per SEC filings the three-year EPS CAGR has been weak; the market expects improvement that history has not yet delivered.
| Ticker | Name | F-Score | ROE | Revenue YoY | Op. margin |
|---|---|---|---|---|---|
| ABBV | AbbVie | 8/9 | 15 367% |
Quarter-by-quarter classification · a retrospective read by the current logic · not a price forecast
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice. The method did not see these quarters in real time; this is the current logic applied to past reports.
The market prices in earnings growth; analyst sentiment is strengthening; has mostly beaten consensus.
Price against next year's expected earnings. The forward P/E already carries analyst optimism — read it alongside the “Versus consensus” line.
A forward P/E below the current one means the market expects earnings to grow; above it, to fall. The historical growth is realized figures from SEC filings, not a forecast.
The three-month change in the share of positive analyst ratings. This is sentiment, not an earnings-estimate revision, and not a call to act.
When CVS reports on August 5, track operating margin against the current 19.1% sector median — CVS sits 94% below it. Also watch whether FCF growth, up 318% versus the sector median, holds or reverts, and check the F-Score profitability sub-score for any change from its current 3/4.
On SEC EDGAR, open CVS Health's most recent 10-K and read the Liquidity and Capital Resources section. The Debt/EBITDA of 2.93× sits 2.2× above the sector median, and the Leverage and Liquidity sub-score is 1/3 — management's discussion should explain the repayment schedule and any covenant constraints.
Pick two or three names from the alphabetical same-sector table in section 06 and line up one metric — Debt/EBITDA or FCF yield are the most relevant given CVS's mixed signals. No company in the table is ranked; the goal is to place CVS's 4.02% FCF yield and 2.93× leverage in a peer context you choose.
Steps you can check yourself, based on the figures in this brief.
Piotroski F-Score: nine binary tests of financial strength from the annual report. A ✓ marks a test passed, a dot (·) a test failed.
Over 4 years: -15%-23%-39%+23%
Over 4 years: 4.143.244.626.53
Over 4 years: +10%+11%+4%+8%
The context on the right shows how each figure compares with the sector median. The trend below tracks the change over recent fiscal years.
Beat consensus in 7 of 8 recent quarters — the company clears estimates regularly (consensus is often set conservatively).
Last quarter's EPS against consensus, plus the estimated date of the next report.
| +9% |
| 25% |
| ABT | Abbott | 6/9 | 13% | +6% | 18% |
| AMGN | Amgen | 7/9 | 106% | +10% | 25% |
| BMY | Bristol-Myers Squibb | 8/9 | 41% | -0% | — |
| CVS | CVS Health Corp. | 6/9 | 2% | +8% | 1% |
| DHR | Danaher | 5/9 | 7% | +3% | 19% |
| GILD | Gilead Sciences | 8/9 | 40% | +2% | 34% |
| ISRG | Intuitive Surgical | 6/9 | 17% | +21% | 29% |
| JNJ | Johnson & Johnson | 4/9 | 35% | +6% | — |
| LLY | Eli Lilly | 7/9 | 101% | +45% | — |
| MRK | Merck | 4/9 | 37% | +1% | — |
| PFE | Pfizer | 5/9 | 9% | -2% | — |
| TMO | Thermo Fisher | 5/9 | 13% | +4% | 17% |
| UNH | UnitedHealth | 7/9 | 18% | +12% | 4% |
A sample of 14 companies in the sector including the target, alphabetical, unranked. Data from the latest SEC annual reports.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
A simplified retrospective read: no analyst forecast (not available historically); the source is the annual report as of the date, so neighbouring quarters can rest on the same data. Quarters with the same classification in a row are merged into one row — each row is one change in the read, not a separate quarter. One ticker is an illustration of the classification logic, not statistics. How we calculate →
The last few quarters are recent context, not a fixed rate. Consensus for near quarters is set low, so companies clear it routinely; over long horizons the forecasts run the other way, too high.
A description of what the market and analysts expect. Not a price forecast and not investment advice. Analyst forecasts run systematically optimistic over long horizons — read them with that discount.